Literature DB >> 27075830

Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.

Kentaro Kohagura1,2, Takeshi Tana3, Akira Higa3, Masanobu Yamazato2, Akio Ishida2, Kazufumi Nagahama2, Atsushi Sakima2, Kunitoshi Iseki4,5, Yusuke Ohya1,2.   

Abstract

Hyperuricemia may promote the progression of hypertension and renal dysfunction. However, the effects of hyperuricemia treatment on blood pressure and renal function in adult hypertensive patients with hyperuricemia remain unclear. A total of 137 hypertensive patients with hyperuricemia (96 men and 41 women; mean age of 67 years) who recently started taking xanthine oxidase inhibitors (allopurinol or febuxostat) as outpatients were recruited. Serum uric acid level, estimated glomerular filtration rate (eGFR, ml min(-1) per 1.73 m(2)) and blood pressure (mm Hg) were retrospectively compared immediately before and shortly after starting treatment with xanthine oxidase inhibitors. The mean blood pressure and the eGFR immediately before starting treatment were 128/71 mm Hg and 44.6 ml min(-1) per 1.73 m(2), respectively. Although the eGFR decreased from 46.6 to 44.6 ml min(-1) per 1.73 m(2) before starting treatment with xanthine oxidase inhibitors, it increased to 46.2 ml min(-1) per 1.73 m(2) (P=0.001, compared with immediately before treatment) without any significant changes in blood pressure after the administration of xanthine oxidase inhibitors. Multiple regression analysis revealed that the increase in eGFR after starting xanthine oxidase inhibitor treatment positively correlated with the changes in systolic blood pressure and negatively correlated with the changes in uric acid levels and the use of renin-angiotensin system inhibitors. These results suggest that xanthine oxidase inhibitors may delay the progression of renal dysfunction in adult hypertensive patients with hyperuricemia.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27075830     DOI: 10.1038/hr.2016.37

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  27 in total

1.  Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.

Authors:  Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan.

Authors:  Chung-Sheng Lin; Wen-Ling Lee; Yi-Jen Hung; Du-Yi Lee; Kuei-Feng Chen; Wen-Che Chi; Shin-Chieh Chang
Journal:  Int J Cardiol       Date:  2010-11-20       Impact factor: 4.164

Review 3.  Uric acid and chronic kidney disease: which is chasing which?

Authors:  Richard J Johnson; Takahiko Nakagawa; Diana Jalal; Laura Gabriela Sánchez-Lozada; Duk-Hee Kang; Eberhard Ritz
Journal:  Nephrol Dial Transplant       Date:  2013-03-29       Impact factor: 5.992

4.  Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.

Authors:  Marilda Mazzali; John Kanellis; Lin Han; Lili Feng; Yi-Yang Xia; Qiang Chen; Duk-Hee Kang; Katherine L Gordon; Susumu Watanabe; Takahiko Nakagawa; Hui Y Lan; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2002-06

Review 5.  Hyperuricemia and incident hypertension: a systematic review and meta-analysis.

Authors:  Peter C Grayson; Seo Young Kim; Michael LaValley; Hyon K Choi
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-01       Impact factor: 4.794

6.  Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Taku Inoue; Chiho Iseki; Kozen Kinjo; Shuichi Takishita
Journal:  Am J Kidney Dis       Date:  2004-10       Impact factor: 8.860

7.  Uric acid reduction rectifies prehypertension in obese adolescents.

Authors:  Beth Soletsky; Daniel I Feig
Journal:  Hypertension       Date:  2012-09-24       Impact factor: 10.190

8.  Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan.

Authors:  Kazufumi Nagahama; Kunitoshi Iseki; Taku Inoue; Takashi Touma; Yosiharu Ikemiya; Shuichi Takishita
Journal:  Hypertens Res       Date:  2004-04       Impact factor: 3.872

9.  Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.

Authors:  Yugo Shibagaki; Iwao Ohno; Tatsuo Hosoya; Kenjiro Kimura
Journal:  Hypertens Res       Date:  2014-06-19       Impact factor: 3.872

10.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

View more
  13 in total

Review 1.  Hyperuricemia and Hypertension: Links and Risks.

Authors:  Douglas J Stewart; Valerie Langlois; Damien Noone
Journal:  Integr Blood Press Control       Date:  2019-12-24

2.  Effects of uric-acid-lowering therapy on renal outcomes: the future looks promising.

Authors:  Vassilis Filiopoulos
Journal:  Hypertens Res       Date:  2016-05-19       Impact factor: 3.872

Review 3.  Dietary and commercialized fructose: Sweet or sour?

Authors:  Aslihan Yerlikaya; Tuncay Dagel; Christopher King; Masanari Kuwabara; Miguel A Lanaspa; Ana Andres-Hernando; Adrian Covic; Jacek Manitius; Alan A Sag; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2017-02-16       Impact factor: 2.370

4.  The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.

Authors:  Takayuki Tsuji; Kazuhisa Ohishi; Asumi Takeda; Daiki Goto; Taichi Sato; Naro Ohashi; Yoshihide Fujigaki; Akihiko Kato; Hideo Yasuda
Journal:  Clin Exp Nephrol       Date:  2018-04-26       Impact factor: 2.801

Review 5.  Oxidative Stress and Hypertensive Diseases.

Authors:  Roxana Loperena; David G Harrison
Journal:  Med Clin North Am       Date:  2016-10-27       Impact factor: 5.456

6.  Association of serum uric acid with subsequent arterial stiffness and renal function in normotensive subjects.

Authors:  Shiori Nagano; Maasa Takahashi; Nobuyuki Miyai; Mayumi Oka; Miyoko Utsumi; Mitsuru Shiba; Kanae Mure; Tatsuya Takeshita; Mikio Arita
Journal:  Hypertens Res       Date:  2017-02-16       Impact factor: 3.872

Review 7.  Oxidative stress in chronic kidney disease.

Authors:  Kristien Daenen; Asmin Andries; Djalila Mekahli; Ann Van Schepdael; François Jouret; Bert Bammens
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

Review 8.  Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review.

Authors:  Usama A A Sharaf El Din; Mona M Salem; Dina O Abdulazim
Journal:  J Adv Res       Date:  2016-12-03       Impact factor: 10.479

Review 9.  Natural Bioactive Compounds As Protectors Of Mitochondrial Dysfunction In Cardiovascular Diseases And Aging.

Authors:  Diego Arauna; María Furrianca; Yolanda Espinosa-Parrilla; Eduardo Fuentes; Marcelo Alarcón; Iván Palomo
Journal:  Molecules       Date:  2019-11-22       Impact factor: 4.411

10.  Evaluation of the Effectiveness of Xanthine Oxidoreductase Inhibitors on Haemodialysis Patients using a Marginal Structural Model.

Authors:  Takeo Ishii; Masataka Taguri; Kouichi Tamura; Kunio Oyama
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.